Moderna, Inc. R&D Expense

Quick Answer

Moderna, Inc. reported R&D Expense of $3.13 billion for fiscal year 2025.

Moderna, Inc. R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2025 $3.13B -31.1%
2024 $4.54B -6.2%
2023 $4.84B +47.0%
2022 $3.29B +65.5%
2021 $1.99B +45.3%
2020 $1.37B +176.2%
2019 $496.00M +9.2%
2018 $454.08M +10.6%
2017 $410.46M +49.4%
2016 $274.72M

Quarterly R&D Expense

Quarter Ending R&D Expense YoY QoQ
September 30, 2025 $801.00M -29.6% +14.4%
June 30, 2025 $700.00M -42.7% -18.2%
March 31, 2025 $856.00M -19.5% -24.7%
September 30, 2024 $1.14B -2.0% -6.9%
June 30, 2024 $1.22B +6.4% +14.9%
March 31, 2024 $1.06B -6.0% -8.4%
September 30, 2023 $1.16B +41.5% +1.0%
June 30, 2023 $1.15B +61.7% +1.5%
  • Moderna, Inc. showed a decrease of -31.1% in R&D Expense compared to the prior fiscal year.
  • Over the 2016–2025 period, Moderna, Inc.’s r&d expense has grown by 1040.1% (from $274.72 million to $3.13 billion).
  • The most recent figure is from Moderna, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 20, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment